Durata Therapeutics (DRTX +2.4%) says its Phase III study of dalbavancin, which is under...

|About: Durata Therapeutics (DRTX)|By:, SA News Editor

Durata Therapeutics (DRTX +2.4%) says its Phase III study of dalbavancin, which is under investigation for the treatment of acute bacterial skin infections, achieved its primary endpoint within 48-72 hours after initiation of therapy. The company added that the key secondary endpoints achieved were also supportive of the primary endpoint.